Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T66093
(Former ID: TTDI02264)
|
|||||
Target Name |
Hepatitis C virus microRNA miR-122 (HCV MIR122)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Hepatitis virus infection [ICD-11: 1E50-1E51] | |||||
BioChemical Class |
Non-coding RNA target
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | Miravirsen | Drug Info | Phase 2 | Hepatitis C virus infection | [2] | |
2 | RG-101 | Drug Info | Phase 2 | Hepatitis C virus infection | [3] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 2 Modulator drugs | + | ||||
1 | Miravirsen | Drug Info | [4] | |||
2 | RG-101 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Company report (Isis Pharmaceuticals) | |||||
REF 2 | 2011 Pipeline of Santaris Pharma. | |||||
REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040120) | |||||
REF 4 | Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.Nucleic Acids Res.2014 Jan;42(1):609-21. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.